Evaluation of Cardiovascular Risk of Selective and Nonselective Cyclooxygenase Inhibitors (COX-Is) in Arthritic Patients: A Comparative Matched Case Control Study

N. Quraishi, U. Bhosale, R. Yegnanarayan, D. Devasthale
2014 Journal of Scientific Research  
This study was conducted to assess and compare the cardiovascular risk and to explore the demography of CV risk of nonselective cyclooxygenase inhibitors (COX-Is) and selective COX-2-Is in arthritic patients. In this comparative matched case control study adult arthritic patients of either sex taking COX-Is for >1 yr; were included. Arthritic age and sex matched individuals with no history of COX-Is treatment were the controls. Patients with history of any other disease (e.g. diabetes,
more » ... diabetes, hypertension, stroke, IHD etc.) were excluded. Patients were grouped into Control, nonselective COX-I and selective COX-2-I groups. The CV risk factors like blood pressure, blood sugar level (BSL), lipid profile, BMI (body mass index) etc. were assessed and compared; demography of CV risk factors i.e. age, sex, smoking, alcohol, heredity was also studied. Qualitative data were analyzed using Chi-square and quantitative data were analyzed by student's't'-test. Study clearly revealed that all NSAIDs exhibit significant CV risk when taken over a period of time as in arthritis. However selective COX 2-Is found to exhibit more CV risk in this regard. Odds ratio (OR) for CV risk = 10.3 (95% CI: 1.45, 3.31) and OR for CV risk = 5.2 (95%CI: 1.05, 2.57) for nonselective COX-Is. BMI, BSL and lipid profile; the potential CV risk factors, showed significant impairment in selective COX 2-Is group; P<0.05, P<0.05 and P<0.01 (HDL), P<0.001 (cholesterol), respectively compared to controls and P<0.05 compared to nonselective COX-Is. This study portrays the potential CV risk of selective COX 2-Is and confirms and re-evaluate the results of earlier studies in this regard.
doi:10.3329/jsr.v6i2.17039 fatcat:ml4f5mxnvrhlhgq4mwo4dtwyli